Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology

Li, Junzhi; Lockerbie, Owen; Korte, Dirk de; Rice, Joe; McLean, R.M.; Goodrich, Raymond P.

doi:10.1111/j.1537-2995.2005.04381.x

Cited by 45 publications

(59 citation statements)

References 30 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical studies have demonstrated that pH value is a simple parameter which indirectly indicates the condition of platelets and correlates with in vivo platelet recovery. 19,20 It has been determined that the mean platelet volume decreases in all components stored at room temperature, which confirms the satisfactory condition of cells.…”

Section: Discussionmentioning

confidence: 59%

“…Many authors claim that parameters such as aggregation capacity or HSR represent the in vivo hemostatic functions of platelets, but the most reliable, conclusive method of demonstrating PC transfusion effectiveness would be to evaluate the patient's clinical state following the transfusion of PRT-treated PCs. 20,30 Independently of the above-described in vitro studies, each regional blood transfusion center involved in PC inactivation also performs routine quality control of inactivated PCs and monitors the components. If the percentage of components within a normal range falls below 75%, corrective measures are launched which consist of monitoring all stages of inactivated PC preparation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience

Lachert¹,

Kubis²,

Antoniewicz‐Papis³

et al. 2018

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Discussionmentioning

confidence: 99%

Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience

Lachert¹,

Kubis²,

Antoniewicz‐Papis³

et al. 2018

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…Marschner/Goodrich spite the fact that mitochondrial DNA is fragmented by the treatment [11], the wavelength of UV light used in the process is distinct from the one where cytochrome C, FMN and FAD absorb (370-450 nm) [46], resulting in intact electron transfer processes within mitochondrial membranes. Low oxygen levels in the treated products are a simple measurement and indication of functional mitochondria, since oxygen is consumed and ATP produced during mitochondrial respiration [44,45]. Additional evidence that mitochondria are intact after Mirasol treatment comes from the use of PAS, in which acetate is used as a substitute for glucose.…”

Section: Pathogen Reduction and Leukocyte Inactivation Performancementioning

confidence: 99%

Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light

Marschner¹,

Goodrich²

2011

Transfus Med Hemother

177

186

View full text Add to dashboard Cite

Bacterial contamination and emerging infections combined with increased international travel pose a great risk to the safety of the blood supply. Tests to detect the presence of infection in a donor have a ‘window period’ during which infections cannot be detected but the donor may be infectious. Agents and their transmission routes need to be recognized before specific tests can be developed. Pathogen reduction of blood components represents a means to address these concerns and is a proactive approach for the prevention of transfusion-transmitted diseases. The expectation of a pathogen reduction system is that it achieves high enough levels of pathogen reduction to reduce or prevent the likelihood of disease transmission while preserving adequate cell and protein quality. In addition the system needs to be nontoxic, non-mutagenic and should be simple to use. The Mirasol® Pathogen Reduction Technology (PRT) System for Platelets and Plasma uses riboflavin (vitamin B2) plus UV light to induce damage in nucleic acid-containing agents. The system has been shown to be effective against clinically relevant pathogens and inactivates leukocytes without significantly compromising the efficacy of the product or resulting in product loss. Riboflavin is a naturally occurring vitamin with a well-known and well-characterized safety profile. The same methodology is currently under development for the treatment of whole blood, making pathogen reduction of all blood products using one system achievable. This review gives an overview of the Mirasol PRT System, summarizing the mechanism of action, toxicology profile, pathogen reduction performance and clinical efficacy of the process.

show abstract

“…Prior to PRT treatment with the INTERCEPT BLOOD SYSTEM as described previously [19][20][21] [22][23][24]. Untreated C units were resuspended in 150 ml of InterSol plus 30 ml saline to compensate for the addition of photosensitizers.…”

Section: Prt Treatmentmentioning

confidence: 99%

Annexin V Release and Transmembrane Mitochondrial Potential during Storage of Apheresis-Derived Platelets Treated for Pathogen Reduction

Picker

Oustianskaia

Schneider

et al. 2010

Transfus Med Hemother

View full text Add to dashboard Cite

Background: In vitro function of stored platelet (PLT) con-centrates was analyzed after applying two different techniques of pathogen reduction technology (PRT) treatment, which could increase cellular injury during processing and storage. Methods: Nine triple-dose PLT apheresis donations were split into 27 single units designated to riboflavin-UVB (M) or psoralen-UVA (I) treatment or remained untreated (C). Throughout 8 days of storage, samples were analyzed for annexin V release, the mitochondrial transmembrane potential (ΔΨ) and some classical markers of PLT quality (pH, LDH release, hypotonic shock response (HSR)). Results: PLT count and LDH release of all units maintained initial ranges. All units exhibited a decrease in pH and HSR and an increase in annexin V release and ΔΨ disruption. Notably, throughout the entire storage period, annexin V release re-mained lowest in M units. Throughout 7 days of storage, M units remained comparable to C units (p > 0.05), whereas inferior values were observed with I units. Here, differences to C units reached significance by day 1 (pH: p < 0.0001), day 5 (annexin V release: p < 0.014), and day 7 (HSR, ΔΨ: p ≤ 0.003). After PRT treatment, annexin V release and ΔΨ disruption were significantly (p < 0.001) correlated with pH and HSR. Conclusion: During storage, all units showed a de-crease in HSR and an increase in acidity, annexin V release and ΔΨ disruption. While M units remained comparable to C units, I units demonstrated significantly inferior values dur-ing terminal storage. This could have resulted from differences in PRT treatment or simply be due to differences in storage media and should be analyzed for clinical relevance in future investigations.

show abstract

Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology

Cited by 45 publications

References 30 publications

Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience

Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience

Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light

Annexin V Release and Transmembrane Mitochondrial Potential during Storage of Apheresis-Derived Platelets Treated for Pathogen Reduction

Contact Info

Product

Resources

About